SIG
ALXN

Senator Investment Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Senator Investment Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-550,000
Closed -$77.2M – 64
2017
Q3 		$77.2M Sell
550,000
-125,000
-19% -$17M 1.03% 30
2017
Q2 		$82.1M Sell
675,000
-75,000
-10% -$8.73M 0.93% 35
2017
Q1 		$90.9M Buy
750,000
+350,000
+88% +$45.1M 1.12% 32
2016
Q4 		$48.9M Hold
400,000
– – 0.74% 28
2016
Q3 		$49M Buy
400,000
+75,000
+23% +$9.65M 0.65% 43
2016
Q2 		$37.9M Buy
+325,000
New +$46.1M 0.61% 40

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Senator Investment Group's ALXN Position: Q4 2017 in Review

Senator Investment Group sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 550,000 shares — an estimated $77.2M sold.

Senator Investment Group first reported a position in ALXN in Q2 2016 and held it in 6 quarters. The position peaked at $90.9M in Q1 2017. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • Senator Investment Group reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Senator Investment Group sold 550,000 Alexion Pharmaceuticals shares in Q4 2017, an estimated $77.2M.
  • Senator Investment Group first reported a position in Alexion Pharmaceuticals in Q2 2016 and held it in 6 quarters.
  • Senator Investment Group's Alexion Pharmaceuticals position peaked at $90.9M in Q1 2017.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Senator Investment Group's 13F filing for Q4 2017, filed 14 Feb 2018.